Search This Blog

Thursday, November 7, 2019

Stemline Therapeutics EPS beats by $0.12, misses on revenue

Stemline Therapeutics (NASDAQ:STML): Q3 GAAP EPS of -$0.34 beats by $0.12.
Revenue of $13.33M misses by $0.31M.
Shares -4.21% AH.
Press Release
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)